Yahong Pharmaceutical (688176.SH): APL-2401 completed the first phase I clinical trial and enrolled the first patient

Zhitong Finance App News, Yahong Pharmaceutical (688176.SH) announced that the first phase I clinical trial of the APL-2401 developed by the company in advanced solid tumor patients driven by FGFR2/3 has completed the enrollment of the first test subjects.

APL-2401 is a highly selective fibroblast growth factor receptor 2/3 (FGFR2/3) dual-target small molecule inhibitor developed by the company. It is expected to provide a new treatment option for patients with advanced solid tumors (such as urothelial cancer, bile duct cancer, endometrial cancer, stomach cancer, breast cancer, ovarian cancer, non-small cell lung cancer, and other specific solid tumors).